Amryt Pharma Plc Quick Ratio (AMYT) starting from the fourth quarter 2021 to fourth quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Amryt Pharma Plc  (NASDAQ: AMYT)

Amryt Pharma Plc's Quick Ratio

AMYT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2021, Quick Ratio fell to 0.37 below Amryt Pharma Plc average.

Within Major Pharmaceutical Preparations industry 516 other companies have achieved higher Quick Ratio than Amryt Pharma Plc in fourth quarter 2021. While Quick Ratio total ranking has improved so far during the Q4 2021 to 3144, from total ranking in the third quarter 2021 at 3146.

Explain Quick Ratio?
How much Cash & cash equivalents AMYT´s has?
What are AMYT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMYT Quick Ratio (Dec 31 2021)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2020)
Y / Y Current Liabilities Change 62.89 % -14.45 % - - -
Y / Y Cash & cash equivalent Change -4.85 % 68.13 % - - -
Quick Ratio MRQ 0.37 0.72 0.72 0.72 0.63
AMYT's Total Ranking # 3144 # 3146 # 3094 # 0 #
Seq. Current Liabilities Change 95.2 % 0 % 0 % -16.55 % 2.52 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -4.85 % 76.71 %



Quick Ratio fourth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 517
Healthcare Sector # 988
Overall Market # 3144


Quick Ratio Statistics
High Average Low
0.72 0.72 0.72
(Dec 31 2021)  




Financial Statements
Amryt Pharma Plc's Current Liabilities $ 307 Millions Visit AMYT's Balance sheet
Amryt Pharma Plc's Cash & cash equivalent $ 113 Millions Visit AMYT's Balance sheet
Source of AMYT's Sales Visit AMYT's Sales by Geography


Cumulative Amryt Pharma Plc's Quick Ratio

AMYT's Quick Ratio for the trailling 12 Months

AMYT Quick Ratio

 (Dec 31 2021)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2020)
12 Months
Y / Y Current Liabilities TTM Growth 109.19 % 259.19 % - - -
Y / Y Cash & cash equivalent TTM Growth 143.04 % 581.1 % - - -
Quick Ratio TTM 0.58 0.69 0.6 0.56 0.5
Total Ranking TTM # 5722 # 2877 # 0 # 0 #
Seq. Current Liabilities TTM Growth 17.95 % -3.87 % 29.7 % 42.24 % 102.52 %
Seq. Cash & cash equivalent TTM Growth -1.26 % 11.11 % 37.8 % 60.76 % 176.71 %

Quick ratio ranking by company, industry and sector >> Back to AMYT Financial Strength Comparisons >> Go to Compare AMYT Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2021 to $307.01 millions, cumulative Quick Ratio decreased to 0.58 below the Amryt Pharma Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 611 other companies have achieved higher Quick Ratio than Amryt Pharma Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2021 from 2877 to 5722.

Explain Quick Ratio?
How much Cash & cash equivalents AMYT´s has?
What are AMYT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 612
Healthcare Sector # 1217
Within the Market # 5722


trailing twelve months Quick Ratio Statistics
High Average Low
0.72 0.72 0.72
(Dec 31 2021)  




Companies with similar Quick Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2021 MRQ Cash & cash equivalentDec 31 2021 MRQ Current Liabilities
Dynavax Technologies Corporation  0.98 $ 545.950  Millions$ 556.402  Millions
Cti Biopharma Corp   0.96 $ 65.446  Millions$ 67.860  Millions
Organogenesis Holdings Inc   0.96 $ 113.929  Millions$ 119.294  Millions
Johnson and Johnson  0.95 $ 31,608.000  Millions$ 33,131.000  Millions
Allarity Therapeutics Inc   0.95 $ 19.555  Millions$ 20.621  Millions
Vireo Growth Inc.  0.95 $ 25.513  Millions$ 26.921  Millions
Lifevantage Corp  0.92 $ 23.174  Millions$ 25.199  Millions
One World Products Inc   0.90 $ 1.376  Millions$ 1.524  Millions
One World Products Inc   0.90 $ 1.376  Millions$ 1.524  Millions
Orphazyme A  0.85 $ 16.663  Millions$ 19.648  Millions
Biophytis Sa  0.83 $ 26.797  Millions$ 32.166  Millions
Intercept Pharmaceuticals inc   0.81 $ 91.325  Millions$ 112.381  Millions
Grifols Sa  0.78 $ 3,028.818  Millions$ 3,891.229  Millions
Puma Biotechnology Inc   0.75 $ 82.106  Millions$ 109.586  Millions
Petros Pharmaceuticals inc   0.74 $ 17.144  Millions$ 23.054  Millions
Endo International Plc  0.74 $ 1,631.310  Millions$ 2,195.665  Millions
Abbott Laboratories  0.73 $ 10,249.000  Millions$ 13,953.000  Millions
Bristol myers Squibb Company  0.71 $ 16,966.000  Millions$ 23,910.000  Millions
Kineta Inc   0.70 $ 12.909  Millions$ 18.312  Millions
Ensysce Biosciences Inc   0.70 $ 12.265  Millions$ 17.461  Millions
Biohaven Ltd   0.68 $ 364.593  Millions$ 534.202  Millions
Gridai Technologies Corp  0.67 $ 8.249  Millions$ 12.300  Millions
Collegium Pharmaceutical Inc   0.67 $ 186.426  Millions$ 280.220  Millions
Agile Therapeutics Inc  0.65 $ 19.143  Millions$ 29.278  Millions
Jazz Pharmaceuticals Plc  0.63 $ 591.448  Millions$ 937.562  Millions
Sanofi  0.63 $ 12,121.578  Millions$ 19,379.811  Millions
Protokinetix Incorporated  0.62 $ 0.058  Millions$ 0.093  Millions
Stealth Biotherapeutics Corp  0.61 $ 47.135  Millions$ 77.520  Millions
Mallinckrodt Plc  0.59 $ 1,345.000  Millions$ 2,275.700  Millions
Akebia Therapeutics Inc   0.57 $ 149.800  Millions$ 263.564  Millions

Date modified: 2023-03-22T13:18:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.